Chemren Bio-Engineering Co., Ltd.

Products > Others > > Lasmiditan
Product name : Lasmiditan
Item : CR2031
CAS : 439239-90-4
 Enlarge Image                   Back
←[Previous Product]              [Next Product]→


Details:

Biological Activity of Lasmiditan

Lasmiditan (COL-144; LY573144) is a high-affinity, highly selective 5-HT1F receptor agonist(Ki=2.1 nM),  compared with Ki of 1043 nM and 1357 nM at the 5-HT(1B) and 5-HT(1D) receptors, respectively.
IC50 value: 2.1 nM (Ki, 5-HT1F); >1000 nM (Ki, 5-HT1B/5-HT1D) [1]
Target: 5-HT1F receptor
in vitro: In vitro binding studies Lasmiditan showed a K(i) value of 2.21 nM at the 5-HT(1F) receptor, compared with K(i) values of 1043 nM and 1357 nM at the 5-HT(1B) and 5-HT(1D) receptors, respectively, a selectivity ratio greater than 470-fold. Lasmiditan showed higher selectivity for the 5-HT(1F) receptor relative to other 5-HT(1) receptor subtypes than the first generation 5-HT(1F) receptor agonist LY334370. Unlike the 5-HT(1B/1D) receptor agonist sumatriptan, lasmiditan did not contract rabbit saphenous vein rings, a surrogate assay for human coronary artery constriction, at concentrations up to 100 μM [1].
in vivo: In two rodent models of migraine, oral administration of lasmiditan potently inhibited markers associated with electrical stimulation of the trigeminal ganglion (dural plasma protein extravasation, and induction of the immediate early gene c-Fos in the trigeminal nucleus caudalis) [1]. Two RCTs in the phase II development of lasmiditan was reviewed. In the intravenous placebo-controlled RCT, lasmiditan doses of 2.5-45 mg were used, and there was a linear association between headache relief (HR) rates and dose levels (P < 0.02). For lasmiditan 20 mg, HR was 64 % and for placebo it was 45 % (NS). In the oral placebo-controlled RCT, lasmiditan doses of 50, 100, 200 and 400 mg were used. For HR, all doses of lasmiditan were superior to placebo (P < 0.05). For lasmiditan 400 mg, HR was 64 % and it was 25 % for placebo. Adverse events (AEs) emerging from the treatment were reported by 22 % of the patients receiving placebo and by 65, 73, 87 and 87 % of patients receiving 50, 100, 200 and 400 mg, respectively [2].

Chemical Information

M.Wt 377.36 Storage Please store the product under the recommended conditions in the Certificate of Analysis.
Formula C19H18F3N3O2
CAS No 439239-90-4
Solvent & Solubility

10 mM in DMSO

Preparing Stock Solutions

1 mg 5 mg 10 mg
1 mM 2.6500 mL 13.2499 mL 26.4999 mL
5 mM 0.5300 mL 2.6500 mL 5.3000 mL
10 mM 0.2650 mL 1.3250 mL 2.6500 mL

Clinical Information of Lasmiditan

Product Name Sponsor Only Condition Start Date End Date Phase Last Change Date
Lasmiditan CoLucid Pharmaceuticals Inc Migraine 31-OCT-06 30-JUN-07 Phase 2 02-DEC-13
CoLucid Pharmaceuticals Inc Migraine 31-JUL-09 28-FEB-10 Phase 2 02-DEC-13

References on Lasmiditan


Availability and price:
Stock : in stock
We offer significant discount for larger quantity order.
For quotation, question, and order, please send email to :sales@chemrenpharm.com

Related Products :
AGN 194310
AGN 194310
YF-476(Netazepide)
YF-476(Netazepide)
Bohemine
Bohemine
RQ-00203078
RQ-00203078
AGI-5198
AGI-5198
Osilodrostat (LCI699)
Osilodrostat (LCI699)
SR1078
SR1078
S-Ruxolitinib (INCB018424)
S-Ruxolitinib (INCB018424)

Online service

点击这里给我发消息